文献速递胃肠动力与功能性疾病炎症性肠病

肠易激综合征患者与溃疡性结肠炎患者及健康对照者的代谢组学特征比较:对病理生理学和潜在生物标志物的新见解

Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.
PubMed 文献 · Aliment Pharmacol Ther · 2019-01-31

研究收集39例肠易激综合征患者、53例临床缓解期溃疡性结肠炎患者和21例健康对照者的尿液,采用直接输注/液相色谱串联质谱和气相色谱质谱法检测代谢物。肠易激综合征患者具有独特尿液代谢组,可与溃疡性结肠炎患者区分(曲线下面积=0.99,95%置信区间0.95-1.00),亦可与健康对照者区分;部分代谢物水平与症状严重程度评分显著相关。

要点

  • 肠易激综合征患者尿液代谢组可将其与临床缓解期溃疡性结肠炎患者区分,曲线下面积=0.99(95%置信区间0.95-1.00)。
  • 区分最重要的代谢物为氨基酸和有机酸类。
  • 肠易激综合征患者尿液磷脂酰胆碱酰基-烷基C38:6、多巴胺和对羟基苯甲酸低于健康对照者。

核心结论

  • 肠易激综合征患者与临床缓解期溃疡性结肠炎患者或健康受试者相比具有独特的尿液代谢组学特征。
  • 这些数据提示代谢组学分析可能为病理生理学提供重要见解,并提供可检验的生物标志物以区分肠易激综合征与其他可模仿该病的疾病,以及评估其严重程度和识别潜在的新病理生理通路。

研究设计与样本

  • 研究收集39例肠易激综合征患者、53例临床缓解期溃疡性结肠炎患者和21例健康对照者的尿液样本。
  • 采用直接输注/液相色谱串联质谱和气相色谱质谱法鉴定和定量尿液代谢物。

主要发现

  • 肠易激综合征患者具有独特尿液代谢组,可与溃疡性结肠炎患者区分,曲线下面积=0.99(95%置信区间0.95-1.00)。
  • 区分最重要的代谢物为氨基酸和有机酸类。
  • 肠易激综合征受试者可通过代谢指纹与健康对照者区分。
  • 肠易激综合征患者尿液磷脂酰胆碱酰基-烷基C38:6、多巴胺和对羟基苯甲酸低于健康对照者。
  • 包括组胺在内的部分尿液代谢物水平与肠易激综合征症状严重程度评分显著相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evaluation of the metabolomic profile of patients with irritable bowel syndrome offers an opportunity to identify novel pathophysiological targets and biomarkers that could discriminate this disorder from related conditions. AIM: To identify potential urinary biomarkers that discriminate irritable bowel syndrome patients from ulcerative colitis patients in remission and healthy controls and to explore the pathophysiology of irritable bowel syndrome using a metabolomic approach. METHODS: Urine samples were collected from 39 irritable bowel syndrome patients, 53 ulcerative colitis patients in clinical remission and 21 healthy controls. Urinary metabolites were identified and quantified using direct infusion/liquid chromatography tandem mass spectrometry and gas-chromatography mass spectrometry. RESULTS: Patients with irritable bowel syndrome had a unique urinary metabolome that could separate them from ulcerative colitis patients with an area under the curve = 0.99 (95% confidence interval 0.95-1.00). The most important metabolites for this separation were a group of amino acids and organic acids. In addition, subjects with irritable bowel syndrome could be discriminated from healthy controls using their metabolic fingerprints. Irritable bowel syndrome patients had lower urinary Phosphatidyl choline acyl-alkyl C38:6, dopamine and p-hydroxybenzoic acid than healthy controls. Levels of some urinary metabolites including histamine correlated significantly with irritable bowel syndrome symptom severity scores. CONCLUSIONS: Irritable bowel syndrome patients have a unique urinary metabolomic profile compared to ulcerative colitis patients in clinical remission or healthy subjects. These data suggest that metabolomic profiling may provide important insights into pathophysiology and testable biomarkers to discriminate irritable bowel syndrome from other disorders that can mimic this condition and can be used to assess its severity and identify potential novel pathophysiological pathways.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Keshteli AH, Madsen KL, Mandal R, et al. Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther. 2019. PMID: 30706502. doi:10.1111/apt.15141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。